Xvivo Perfusion Management
Management criteria checks 3/4
Xvivo Perfusion's CEO is Christoffer Rosenblad, appointed in Jan 2022, has a tenure of 2.58 years. directly owns 0.18% of the company’s shares, worth SEK27.42M. The average tenure of the management team and the board of directors is 3.8 years and 3.8 years respectively.
Key information
Christoffer Rosenblad
Chief executive officer
SEK 5.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.6yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.8yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?
Aug 03
Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Apr 25There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital
Apr 11Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates
Feb 05We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings
Feb 01Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jan 28Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled
Aug 24Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching
Jul 17Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?
Jun 16Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital
Apr 19Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?
Mar 23With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case
Mar 07When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?
Feb 13Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital
Dec 14Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?
Nov 17Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively
Aug 20Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are
Jul 21Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital
Mar 30At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?
Feb 18A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)
Jan 30CEO
Christoffer Rosenblad (49 yo)
2.6yrs
Tenure
SEK 5,031,000
Compensation
Mr. Christoffer Rosenblad serves as Chief Executive Officer at Xvivo Perfusion AB (publ) since November 30, 2022. He served as Deputy Chief Executive Officer and Global Business Development & Service Direc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 2.6yrs | SEK 5.03m | 0.18% SEK 27.4m | |
| Chief Financial Officer | 3.8yrs | no data | 0.0085% SEK 1.3m | |
| Chief Operating Officer | 1.7yrs | no data | 0.0063% SEK 986.1k | |
| Global Human Resources Director | 1.6yrs | no data | no data | |
| Senior Advisor | 4.2yrs | SEK 1.62m | no data | |
| Chief Medical Officer | 3.9yrs | no data | 0.011% SEK 1.7m | |
| Chief Commercial Officer | 3.9yrs | no data | 0.012% SEK 1.8m |
3.8yrs
Average Tenure
54yo
Average Age
Experienced Management: XVIVO's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 11.6yrs | SEK 440.00k | 0.015% SEK 2.3m | |
| Independent Director | 3.8yrs | no data | 0.0076% SEK 1.2m | |
| Independent Director | 1.3yrs | no data | 0.18% SEK 27.4m | |
| Independent Director | 8.3yrs | SEK 130.00k | 0.0034% SEK 531.1k | |
| Independent Director | 3.8yrs | no data | 0.0041% SEK 641.4k | |
| Independent Director | 2.3yrs | no data | no data |
3.8yrs
Average Tenure
63.5yo
Average Age
Experienced Board: XVIVO's board of directors are considered experienced (3.8 years average tenure).